Crossbow Therapeutics raised $77 million in Series B financing to support completion of CROSSCHECK‑001 Ph 1 clinical trial of CBX‑250, and accelerate development of additional T‑Bolt™ immunotherapies
“This financing not only strengthens our ability to advance CBX‑250 through clinical development but also accelerates our mission to bring next‑generation TCR‑mimetic immunotherapies to patients who urgently need new options,” said Briggs Morrison, M.D., Chief Executive Officer of Crossbow Therapeutics. “We greatly appreciate our investors for sharing our conviction in the transformative potential of our T‑Bolt™ platform. We look forward to efficiently expanding our pipeline to address cancers that remain beyond the reach of today’s therapies.”
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines